Scholarlink

Objective <p>This study aimed to assess the efficacy of the oXiris® filter in CRRT for SA-AKI and its effects on short- and medium-term mortality.</p> Methods <p>A retrospective cohort study was conducted at the Blood Purification Center of the First Affiliated Hospital of Zhengzhou University from November 2019 to November 2024. Patients with SA-AKI undergoing CRRT were divided into two groups: the M150 group (<i>n</i> = 135) and the oXiris group (<i>n</i> = 126). Laboratory indices, clinical characteristics, and mortality rates at 7, 14, 30, 60, and 90&#xa0;days were compared between groups to assess the impact of the oXiris filter.</p> Results <p>Following CRRT, the oXiris group showed a significant increase in MAP (76.24 ± 13.21 vs. 82.34 ± 14.38&#xa0;mmHg, <i>p</i> &lt; 0.001), with a decrease in SI (0.96 [0.75, 1.15] vs. 0.80 [0.64, 1.00], <i>p</i> &lt; 0.001), Lac (3.00 [1.70, 6.55] vs. 2.00 [1.40, 3.10] mmol/L, <i>p</i> &lt; 0.001), and IL-6 (174.40 [51.21, 1474.44] vs. 127.20 [35.29, 655.30] pg/ml, <i>p</i> = 0.045) compared to baseline, whereas no such changes were observed in the M150 group. Additionally, the total norepinephrine dose was lower in the oXiris group (108.00[16.00,295.50] vs. 194.00[18.00,500.00] mg, <i>p</i> = 0.020). No significant differences in 7-day, 14-day, 30-day, 60-day, or 90-day mortality were observed between the groups after CRRT initiation.</p> Conclusion <p>The oXiris filter improves short-term hemodynamics, inflammation, and microcirculatory dysfunction in SA-AKI, but does not reduce short- or medium-term mortality compared to the M150 group.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and prognostic analysis of the oXiris® filter in sepsis-associated acute kidney injury

  • 期刊论文

  • 发表日期：

    2025年4月24日

查看全文
  • Si-qi He,
  • Jing Lou,
  • Yan-sheng Li,
  • Yan-na Dou,
  • Lin Yang

摘要

Objective

This study aimed to assess the efficacy of the oXiris® filter in CRRT for SA-AKI and its effects on short- and medium-term mortality.

Methods

A retrospective cohort study was conducted at the Blood Purification Center of the First Affiliated Hospital of Zhengzhou University from November 2019 to November 2024. Patients with SA-AKI undergoing CRRT were divided into two groups: the M150 group (n = 135) and the oXiris group (n = 126). Laboratory indices, clinical characteristics, and mortality rates at 7, 14, 30, 60, and 90 days were compared between groups to assess the impact of the oXiris filter.

Results

Following CRRT, the oXiris group showed a significant increase in MAP (76.24 ± 13.21 vs. 82.34 ± 14.38 mmHg, p < 0.001), with a decrease in SI (0.96 [0.75, 1.15] vs. 0.80 [0.64, 1.00], p < 0.001), Lac (3.00 [1.70, 6.55] vs. 2.00 [1.40, 3.10] mmol/L, p < 0.001), and IL-6 (174.40 [51.21, 1474.44] vs. 127.20 [35.29, 655.30] pg/ml, p = 0.045) compared to baseline, whereas no such changes were observed in the M150 group. Additionally, the total norepinephrine dose was lower in the oXiris group (108.00[16.00,295.50] vs. 194.00[18.00,500.00] mg, p = 0.020). No significant differences in 7-day, 14-day, 30-day, 60-day, or 90-day mortality were observed between the groups after CRRT initiation.

Conclusion

The oXiris filter improves short-term hemodynamics, inflammation, and microcirculatory dysfunction in SA-AKI, but does not reduce short- or medium-term mortality compared to the M150 group.